Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose escalation and expansion of SGN-LIV1A administered weekly in breast cancer.
Jame Abraham, MD on A Phase I Open Label Study of SGN-LIV1A: Antibody Drug Conjugate #ASCO2020 @CleClinicMD @jamecancerdoc
